Posters

      Quantification Of The Effect Of Smoking And Smoking Cessation On Lipid Parameters: A Meta-Analysis

      Gonzalez-Zuloeta, A. M.; de La Bourdonnaye, G.; Baker, G. S.; Weitkunat, R.; Lüdicke, F.
      Conference date
      Sep 21, 2013
      Conference name

      ACE 2013
      Link to more information
      Topic
      Summary

      Purpose: To quantify the effect of smoking and smoking cessation on lipid levels. Methods: PubMed was searched to identify publications which reported lipid levels in smokers and non-smokers, as well as articles reporting the effect of smoking cessation on these lipid parameters. A fixed effect model was used to perform the meta-analyses in Revman version 5 if there were at least 3 studies evaluating the same parameter. Results: 17 studies reporting smoking cessation were identified and 70 studies evaluating smoking and lipid parameters levels. We found that smokers had decreased levels of HDL and APO AI.

      Related Publications

      Barriers to stop smoking (BASS): Results and insights from four years of empirical research in Germany

      Perception and Behavior

      Unlocking a decade of tobacco heating system post-market surveillance

      Post-Market Studies and Surveillance Study

      Reasons for oral nicotine product use among adults who smoke or use smoke-free products in Germany - Results from the Barrier to Stopping smoking (BASS) survey

      Perception and Behavior

      Misunderstanding nicotine delivery: Discussion on nicotine pouches

      Nicotine

      AeroSolved: Wall Boundary Conditions for Liquid Multispecies Aerosol Deposition at Transient and High-Humidity Flows

      Aerosol Physics

      Bridging Approaches to Facilitate Innovation: Building an Approach for Heated Tobacco Products from Case Studies in the Food and Drug Domains a Comparative Review

      Aerosol Chemistry;Pre-clinical Toxicology

      PMIScience.com is operated by Philip Morris International for the purpose of publishing and disseminating scientific information about Philip Morris International’s efforts in support of its smoke-free product portfolio. This site is a global site for use by scientists, the public health and regulatory communities, and other stakeholders with an interest in tobacco policy. The purpose of this site is not advertising or marketing, nor is it directed at any specific market. It is not intended for use by consumers. New tobacco products sold in the United States are subject to FDA regulation; therefore the content of this site is not intended to make, and nor should it be construed as making, any product related claims in the United States without proper FDA authorization. ​
      ​
      Reduced Risk Products ("RRPs”) is the term we use to refer to products that present, are likely to present, or have the potential to present less risk of harm to smokers who switch to these products versus continuing smoking. PMI has a range of RRPs in various stages of development, scientific assessment and commercialization. All of our RRPs are smoke-free products that deliver nicotine with far lower quantities of harmful and potentially harmful constituents than found in cigarette smoke.